Cargando…
Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and les...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175171/ https://www.ncbi.nlm.nih.gov/pubmed/34136291 http://dx.doi.org/10.1155/2021/1717506 |
_version_ | 1783703000735285248 |
---|---|
author | Micheva, Ilina Gerov, Vladimir Dimitrova, Stela Efraim, Merlin |
author_facet | Micheva, Ilina Gerov, Vladimir Dimitrova, Stela Efraim, Merlin |
author_sort | Micheva, Ilina |
collection | PubMed |
description | Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance. |
format | Online Article Text |
id | pubmed-8175171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-81751712021-06-15 Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Micheva, Ilina Gerov, Vladimir Dimitrova, Stela Efraim, Merlin Case Rep Hematol Case Report Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is an aggressive disease with poor outcomes. Despite the incorporation of tyrosine kinase inhibitors (TKIs) in the therapeutic strategies, patients who relapse after chemotherapy plus TKI have poor overall survival (OS) and less chance to proceed to hematopoietic stem cell transplantation (HSCT) which remains the only curative approach. Therefore, new drugs, such as antibody-targeted therapies alone or in combination with TKIs, offer new therapeutic options for those patients. However, the combination of inotuzumab plus ponatinib has limited application. We present a case of a patient affected by Ph + ALL with T315I mutation successfully treated after early relapse with inotuzumab plus ponatinib, followed by allogeneic HSCT and ponatinib maintenance. Hindawi 2021-05-26 /pmc/articles/PMC8175171/ /pubmed/34136291 http://dx.doi.org/10.1155/2021/1717506 Text en Copyright © 2021 Ilina Micheva et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Micheva, Ilina Gerov, Vladimir Dimitrova, Stela Efraim, Merlin Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title | Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title_full | Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title_fullStr | Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title_full_unstemmed | Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title_short | Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
title_sort | efficacy of inotuzumab ozogamicin plus ponatinib followed by allogeneic stem cell transplantation in a patient with relapsed philadelphia chromosome-positive acute lymphoblastic leukemia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175171/ https://www.ncbi.nlm.nih.gov/pubmed/34136291 http://dx.doi.org/10.1155/2021/1717506 |
work_keys_str_mv | AT michevailina efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia AT gerovvladimir efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia AT dimitrovastela efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia AT efraimmerlin efficacyofinotuzumabozogamicinplusponatinibfollowedbyallogeneicstemcelltransplantationinapatientwithrelapsedphiladelphiachromosomepositiveacutelymphoblasticleukemia |